Karyopharm Therapeutics, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -2.44%429.900.0%$5884.05m
BNTXBioNTech SE -4.19%357.040.0%$1230.15m
NVAXNovavax, Inc. -1.81%232.9779.4%$922.32m
SNSSSunesis Pharmaceuticals, Inc. 1.29%8.630.7%$603.27m
AMGNAmgen, Inc. 0.20%217.791.4%$528.97m
REGNRegeneron Pharmaceuticals, Inc. -1.00%646.652.7%$517.55m
GILDGilead Sciences, Inc. -0.66%70.861.0%$418.85m
ILMNIllumina, Inc. -1.25%444.303.5%$375.36m
TECHBio-Techne Corp. 0.10%529.984.5%$328.64m
BIIBBiogen, Inc. -0.57%297.971.7%$291.11m
VRTXVertex Pharmaceuticals, Inc. 0.10%187.291.9%$230.80m
ISEEIVERIC bio, Inc. -0.12%16.340.0%$188.89m
BGNEBeiGene Ltd. 8.20%416.811.3%$172.46m
LIFEaTyr Pharma, Inc. -6.63%9.583.2%$130.09m
KDMNKadmon Holdings, Inc. -0.28%8.800.9%$127.80m

Company Profile

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.